SavedAdd your journal

Journals / Eskisehir Medical Journal / 2026 / Volume: 7 Issue: 1

The Relationship Between Episode Frequency and Functional Capacity in Patients Treated with Implantable Cardioverter Defibrillators

Takılabilir Kardiyoverter Defibrilatörler ile Tedavi Edilen Hastalarda Epizod Sıklığının Fonksiyonel Kapasite ile İlişkisi

Sedat Sakallı(Gaziantep City Hospital)0000-0002-3766-7269
Esra Polat(Health Sciences University, Department of Cardiology, Gaziantep City Hospital)0000-0002-2330-2816
Engin Dondurmacı(Gaziantep City Hospital)0000-0002-7344-0328
Abdurrahman Eren(Health Sciences University, Department of Cardiology, Mehmet Akif Ersoy Thoracic and Cardiovascular Surgery Training and Research Hospital, İstanbul, Turkey)0000-0001-6408-4918
Pages
—
Publication Date
2026-02-24
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The rate of benefit from ICD treatment is higher in patients in the NYHA class III group.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Introduction: Left ventricular ejection fraction (EF) is an important parameter for determining the frequency of ventricular arrhythmia episodes in patients treated with implantable cardioverter defibrillators (ICD).
📊
Key Findings & Data:Methods: The frequency of ventricular arrhythmia episodes was examined in patients who had a ICD implanted between January 1998 and April 2004.
💡
Conclusion & Impact:The rate of benefit from ICD treatment is higher in patients in the NYHA class III group.
🔬Design:Review & Systematic Survey
📍Scope:2004 Verileri
⚙️Variables:Implantable Cardioverter Defibrillator · ventricular tachycardia · ventricular fibrillation

Abstract

Introduction: Left ventricular ejection fraction (EF) is an important parameter for determining the frequency of ventricular arrhythmia episodes in patients treated with implantable cardioverter defibrillators (ICD). However, the relationship between heart failure and ICD episode frequency is controversial. This study aimed to evaluate the relationship between ICD episode frequency and functional capacity in patients classified according to the New York Heart Association (NYHA). Methods: The frequency of ventricular arrhythmia episodes was examined in patients who had a ICD implanted between January 1998 and April 2004. Seventy consecutive patients were retrospectively reviewed. Class I-II, II, and II-III patients were grouped into Group A, and Class III patients were grouped into Group B. The patients' demographic data, echocardiography findings, EFs, NYHA clinical status, indications for ICD implantation, and ICD episodes were examined. Results: The mean follow-up period for patients was 3.08±1.31 years. Two patients were NYHA class I-II, 15 patients were NYHA class II, 41 patients were NYHA class II-III, and 12 patients were NYHA class III. A total of 791 appropriately treated episodes of sustained ventricular tachycardia or ventricular fibrillation were observed in 70 patients. When these episodes were analyzed according to NYHA group, the frequency of ventricular arrhythmia episodes was higher in the Group B patient group (8.36±21.18 vs 25.33±27.63, p=0.019). Conclusions: NYHA class III heart failure is an easily assessable clinical measure and an important risk factor for the need for ICD treatment of ventricular arrhythmias. The rate of benefit from ICD treatment is higher in patients in the NYHA class III group.

Özet

Giriş: Sol ventrikül ejeksiyon fraksiyonu (EF), takılabilir kardiyoverter defibrilatör (ICD) ile tedavi edilen hastalarda ventriküler aritmi epizot sıklığını tespit etmede önemli bir parametredir. Ancak kalp yetmezliği ile ICD epizot sıklığı arasındaki ilişki tartışmalıdır. Bu çalışmada ICD epizot sıklığının New York Heart Association (NYHA)’a göre sınıflandırılmış hastalarda fonksiyonel kapasite ile ilişkisini değerlendirmek amaçlandı. Yöntem: Ocak 1998 ve Nisan 2004 yılları arasında ICD takılan hastalarda ventriküler aritmi epizot sıklığı incelendi. Ardışık 70 hasta retrospektif olarak incelendi. Sınıf I-II, II ve II-III hastalar Grup A, Sınıf III hastalar Grup B olarak gruplandırıldı. Hastaların demografik verileri, ekokardiyografi bulguları, EF’ları, NYHA klinik durumları, ICD takılma endikasyonları ve ICD epizotları incelendi. Bulgular: Hastaların ortalama takip süresi 3.08±1.31 yıl idi. 2 hasta NYHA sınıf I-II, 15 hasta NYHA sınıf II, 41 hasta NYHA sınıf II-III, 12 hasta NYHA sınıf III idi. 70 hastada toplam 791 adet uygun olarak tedavi edilen sustained ventriküler taşikardi ya da ventriküler fibrilasyon atağı vardı. Bu epizotlar NYHA grubuna göre incelendiğinde Grup B’deki hasta grubunda ventriküler aritmi epizot sıklığı daha fazla olarak görüldü. (8.36±21.18 vs 25.33±27.63, p=0.019). Sonuç: NYHA sınıf III kalp yetmezliği kolay değerlendirilebilen bir klinik ölçümdür ve ventriküler aritmilerin ICD ile tedavi gereksiniminde önemli bir risk faktörüdür. ICD tedavisinden yarar görme oranı NYHA sınıf III grubunda olan hastalarda daha fazladır.

🔖

Cite This Article

Sakallı, S., Polat, E., Dondurmacı, E., Eren, A. (2026). The Relationship Between Episode Frequency and Functional Capacity in Patients Treated with Implantable Cardioverter Defibrillators. Eskisehir Medical Journal, Volume: 7 Issue: 1. https://doi.org/10.48176/esmj.2026.231

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (18)

  1. Kumar A, Avishay DM, Jones CR, et al. Sudden cardiac death: epidemiology, pathogenesis and management. Reviews in cardiovascular medicine,2021; 22(1):147-58.
  2. Wong CX, Brown A, Lau DH, et al. Epidemiology of sudden cardiac death: global and regional perspectives. Heart, Lung and Circulation, 2019;28(1): 6-14.
  3. Saour B, Smith B, Yancy CW. Heart Failure and Sudden Cardiac Death. Cardiac electrophysiology clinics, 2017;9(4): 709–23.
  4. Al-Khatib SM, Stevenson WG, Ackerman MJ, et al. 2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Journal of the American College of Cardiology, 2018;72(14): e91-e220.
  5. Elliott PM, Anastasakis A, Borger MA, et al. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J, 2014;35(39): 2733-79.
  6. McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European heart journal, 2021;42(36): 3599–726.
  7. Castel MA, Magnani S, Mont L, et al. Survival in New York Heart Association class IV heart failure patients treated with cardiac resynchronization therapy compared with patients on optimal pharmacological treatment. Europace: European pacing, arrhythmias, and cardiac electrophysiology: journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology, 2010;12(8): 1136–40.
  8. Caraballo C, Desai NR, Mulder H, et al. Clinical Implications of the New York Heart Association Classification. Journal of the American Heart Association, 2019; 8(23): e014240.
  9. Raphael C, Briscoe C, Davies J,et al. Limitations of the New York Heart Association functional classification system and self-reported walking distances in chronic heart failure. Heart (British Cardiac Society), 2007;93(4): 476–82.
  10. Barsheshet A, Goldenberg I, Buturlin K, et al. Competing risks of ventricular tachyarrhythmias and mortality in advanced heart failure: impact of left ventricular ejection fraction. European Heart Journal, 2025;46(Supplement_1).
  11. Goldenberg I, Gillespie J, Moss AJ, et al. Long-term benefit of primary prevention with an implantable cardioverter-defibrillator: an extended 8-year follow-up study of the Multicenter Automatic Defibrillator Implantation Trial II. Circulation, 2010;122(13): 1265–71.
  12. Mehta D, Saksena S, Krol RB, et al. Device use patterns and clinical outcome of implantable cardioverter defibrillator patients with moderate and severe impairment of left ventricular function. Pacing and clinical electrophysiology: PACE, 1993;16 (1 Pt 2): 179–85.
  13. Franciosa JA, Park M, Levine TB. Lack of correlation between exercise capacity and indexes of resting left ventricular performance in heart failure. The American journal of cardiology,1981; 47(1): 33–9.
  14. Whang W, Mittleman MA, Rich DQ, et al. Heart failure and the risk of shocks in patients with implantable cardioverter defibrillators: results from the Triggers Of Ventricular Arrhythmias (TOVA) study. Circulation, 2004;109(11):1386–91.
  15. Nalbantgil S, Çavuşoğlu Y, Akdeniz B, et al. İleri evre kalp yetersizliği rehberi. Kardiyoloji Güncellemeleri Türk Kardiyoloji Derneği Dergisi, 2018;1(1): 1-79.
  16. Böcker D, Bänsch D, Heinecke A, et al. Potential benefit from implantable cardioverter-defibrillator therapy in patients with and without heart failure. Circulation, 1998; 98(16): 1636-43.
  17. Castel MA, Magnani S, Mont L, et al. Survival in New York Heart Association class IV heart failure patients treated with cardiac resynchronization therapy compared with patients on optimal pharmacological treatment. Europace: European pacing, arrhythmias, and cardiac electrophysiology: journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology, 2010;12(8): 1136–40.
  18. Mehta D, Saksena S, Krol RB, et al. Device use patterns and clinical outcome of implantable cardioverter defibrillator patients with moderate and severe impairment of left ventricular function. Pacing and clinical electrophysiology: PACE, 1993;16 (1 Pt 2): 179–85.